First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders
Journal of Inherited Metabolic Disease · 2026-07 · 49 (4)
DOI: 10.1002/jimd.70177 ↗Kurz gefasst
Leitlinie in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 03.06.2026. Verfasst von Giorgia Olivieri und 26 weiteren Autor:innen. Beteiligte Einrichtung: Division of Metabolic Diseases and Hepatology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Amino Acid Metabolism, Inborn Errors. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 306 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: SSIEM, Associazione Italiana Acidemie metilmalonica con omocistinuria cblcAPS, Homocystinuria network australia.
Abstract (Originalsprache)
This guideline summarizes diagnostic and therapeutic approaches based on a systematic literature review and evidence evaluation using the GRADE methodology. Given the limited high‐quality data, expert consensus was additionally obtained through a modified Delphi process. Remethylation disorders are rare inherited conditions that disrupt the methionine–homocysteine cycle and consecutively impair essential methylation dependent metabolic pathways. Remethylation disorders are caused by defects in the cobalamin or folate metabolism. The disorders typically result in elevated homocysteine and often low methionine; combined cobalamin‐related defects also affect mitochondrial methylmalonic acid clearance. The cblC‐ MMACHC defect is the most common cobalamin‐related remethylation disorder. Early‐onset patients usually present with severe neurological and eye symptoms. Late‐onset cases show variable symptoms (e.g., psychiatric, renal, thromboembolic events). Plasma total homocysteine, methionine, methylmalonic acid, serum vitamin B12 (and folates) should be assessed in suspected cases. Early detection through newborn screening is associated with improved clinical outcomes. Betaine as first‐line therapy for methylenetetrahydrofolate reductase deficiency and parenteral hydroxocobalamin for cobalamin‐related defects have reduced mortality and morbidity. Total homocysteine, methionine (and methylmalonic acid) should be kept as close to normal values as achievable. Emerging evidence suggests that early use of high‐dose hydroxocobalamin (> 0.35 mg/kg/day) may improve neurocognitive impairment and may ameliorate eye disease in severe cobalamin‐related defects. A major limitation in current practice is the lack of availability of high concentration hydroxocobalamin formulations for parenteral administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Metabolic Diseases and Hepatology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
- Metabolic and Syndromic Diseases Unit, Regional Coordinating Centre for Rare Diseases. Azienda Ospedaliera Friuli Centrale ASUFC, Udine, Italy.
- Department of Human and Medical Genetics, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
- Associazione Italiana Acidemia Metilmalonica con Omocistinuria; cblC APS, Rome, Italy.
- Neonatology, Clinical University Hospital of Santiago de Compostela, CIBERER, Health Research Institute of Santiago de Compostela (IDIS), RICORS, MetabERN: European Reference Network for Rare Hereditary Metabolic Disord…
- Centro de Referência de Doenças Hereditárias do Metabolismo do Centro Hospitalar Universitário de Coimbra, CR-DHM (CHUC), Praceta Professor Mota Pinto, Coimbra, Portugal.
ORCID-Profile: Birute Burnyte, Francois Feillet, D Sean Froese, Luciana Hannibal, Viktor Kožich, Fanny Mochel, Bernd C Schwahn, Ida Schwartz, Jolanta Sykut-Cegielska, Rolf H Zetterström, Carlo Dionisi-Vici, Martina Huemer
Förderung
- SSIEM
- Associazione Italiana Acidemie metilmalonica con omocistinuria cblcAPS
- Homocystinuria network australia
Zitieren
APA
Olivieri, G., Bordugo, A., Burnyte, B., Costetti, A., Couce, M. L., Diogo, L., Feillet, F., Froese, D. S., Greco, B., Gueant, J. L., Hannibal, L., Hörster, F., Kožich, V., La Marca, G., Manoli, I., Mochel, F., Orazi, L., Pérez, B., Schiff, M., …, & Huemer, M. (2026). First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders. Journal of Inherited Metabolic Disease, 49(4). https://doi.org/10.1002/jimd.70177
Vancouver
Olivieri G, Bordugo A, Burnyte B, Costetti A, Couce ML, Diogo L, et al. First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders. Journal of Inherited Metabolic Disease. 2026;49(4). doi:10.1002/jimd.70177
BibTeX
@article{Olivieri2026,
author = {Olivieri, Giorgia and Bordugo, Andrea and Burnyte, Birute and Costetti, Alessandro and Couce, Maria-Luz and Diogo, Luisa and Feillet, Francois and Froese, D Sean and Greco, Benedetta and Gueant, Jean-Louis and Hannibal, Luciana and Hörster, Friederike and Kožich, Viktor and La Marca, Giancarlo and Manoli, Irini and Mochel, Fanny and Orazi, Lorenzo and Pérez, Belén and Schiff, Manuel and Schwahn, Bernd C and Schwartz, Ida and Stepien, Karolina M and Sykut-Cegielska, Jolanta and Tangeraas, Trine and Zetterström, Rolf H and Dionisi-Vici, Carlo and Huemer, Martina},
title = {First Revision of the Guidelines for the Diagnosis and Management of Remethylation Disorders},
journal = {Journal of Inherited Metabolic Disease},
year = {2026},
volume = {49},
number = {4},
doi = {10.1002/jimd.70177}
}
EUVIMED